Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

60 Degrees Pharmaceuticals (SXTPW) Return on Equity (2023 - 2025)

Historic Return on Equity for 60 Degrees Pharmaceuticals (SXTPW) over the last 3 years, with Q3 2025 value amounting to 2.35%.

  • 60 Degrees Pharmaceuticals' Return on Equity fell 5700.0% to 2.35% in Q3 2025 from the same period last year, while for Sep 2025 it was 2.35%, marking a year-over-year decrease of 5700.0%. This contributed to the annual value of 1.8% for FY2024, which is 22000.0% down from last year.
  • As of Q3 2025, 60 Degrees Pharmaceuticals' Return on Equity stood at 2.35%, which was down 5700.0% from 2.45% recorded in Q2 2025.
  • 60 Degrees Pharmaceuticals' 5-year Return on Equity high stood at 0.39% for Q2 2023, and its period low was 2.54% during Q1 2025.
  • Moreover, its 3-year median value for Return on Equity was 0.67% (2023), whereas its average is 0.98%.
  • In the last 5 years, 60 Degrees Pharmaceuticals' Return on Equity tumbled by -4800bps in 2024 and then plummeted by -24100bps in 2025.
  • Quarter analysis of 3 years shows 60 Degrees Pharmaceuticals' Return on Equity stood at 0.67% in 2023, then plummeted by -136bps to 1.59% in 2024, then plummeted by -48bps to 2.35% in 2025.
  • Its Return on Equity was 2.35% in Q3 2025, compared to 2.45% in Q2 2025 and 2.54% in Q1 2025.